ClinicalTrials.gg
CompletedNCT04288778Updated Mar 30, 2025Results posted

A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes

A Phase 4 interventional study of Canagliflozin + Metformin hydrochloride (Fixed Dose Combination) in Diabetes Mellitus, sponsored by Johnson & Johnson Private Limited. Completed at 10 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Johnson & Johnson Private Limited (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
276
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing canagliflozin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. Canagliflozin · Diabetes Mellitus.

Enrollment
4th of 12
276 · median 84
Started
2020
with 1 other
Phase 4
3 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
Johnson & Johnson Private Limited

Among the 12 studies testing canagliflozin in Diabetes Mellitus, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 4, and was the 9th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 12 studies testing canagliflozin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About canagliflozin

Canagliflozin: first FDA approval 2013 (INVOKANA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing canagliflozin in Diabetes Mellitus as a file.
02

Study summary

The purpose of this study is to assess safety of canagliflozin + metformin hydrochloride immediate Release (IR) fixed-dose combination.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant willing to adhere to diet and exercise regimen as recommended by the investigator
  • Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise, who in investigator's opinion are eligible to receive study drug as per prescribing information along with standard care for management of T2DM
  • Women must be , defined as greater than (>) 45 years of age with amenorrhea for at least 18 months, or > 45 years of age with amenorrhea for at least 6 months and less than (\<) 18 months and a serum follicle stimulating hormone (FSH) level > 40 International Units Per Liter (IU/L), or surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal occlusion), or otherwise be incapable of pregnancy, or sexually active and practicing a highly effective method of , including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, tubal ligation, intrauterine device, double-barrier method (example, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization, and consistent with local regulations regarding use of birth control methods for participant participating in clinical studies, for the duration of their participation in the study, or not sexually active
  • Women of , regardless of age must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and negative UPT at baseline (predose, Day 1)
  • Treatment naive participants or participants on stable antihyperglycemic agent (AHA) therapy (for at least 12 weeks before screening) and have a screening visit Glycosylated () of greater than or equal to (>=) 7.0 percent (%) and less than or equal to (\<=) 10.0 %

Exclusion criteria

Exclusion Criteria:

  • History of liver or renal insufficiency (estimated below 45 milliliter per minute [mL/min]); significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Known allergies, , or intolerance to Canagliflozin, Metformin or Canagliflozin + metformin hydrochloride immediate release (IR) Fixed Dose combination (FDC) or its
  • Use of any other sodium glucose cotransporter 2 (SGLT2) inhibitor within 12 weeks before the screening visit
  • If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after last dose of study medication; or intending to donate ova during such time period
  • History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    Canagliflozin + Metformin Hydrochloride Immediate Release (IR)

    Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration.

    Drug: Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)

Interventions

  • DrugCanagliflozin + Metformin hydrochloride (Fixed Dose Combination)

    Drug pages: CanagliflozinStudies of CanagliflozinCanagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.

    Also known as: JNJ-28431754

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. TEAEs were defined as events that started on or after the study medication start date and time.

    Time frame: Baseline (Day 1) up to 24 weeks

  2. Percentage of Participants With Unexpected Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An adverse event was considered unexpected if the nature or severity was not consistent with the applicable product reference safety information.

    Time frame: Baseline (Day 1) up to 24 weeks

  3. Percentage of Participants With Adverse Drug Reactions (ADRs)

    ADRs were defined as the treatment related TEAEs. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were defined as events that started on or after the study medication start date and time.

    Time frame: Baseline (Day 1) up to 24 weeks

Secondary outcomes

  1. Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24

    Percent change from baseline in HbA1c at Weeks 12 and 24 was reported.

    Time frame: Baseline, Weeks 12 and 24

07

Results

Posted Aug 18, 2023

Participant flow

Participant flow — Overall Study
MilestoneCanagliflozin + Metformin Hydrochloride FDC
Started276
Treated274
Completed265
Not completed11
Withdrew: Withdrawal by subject2
Withdrew: Adverse event5
Withdrew: Non-compliance with study drug1
Withdrew: Other1
Withdrew: Started but not treated2

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. TEAEs were defined as events that started on or after the study medication start date and time.

Time frame:
Baseline (Day 1) up to 24 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Percentage of participantsCanagliflozin + Metformin Hydrochloride FDC
TEAEs41.6
TESAEs1.1
PrimaryPercentage of Participants With Unexpected Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An adverse event was considered unexpected if the nature or severity was not consistent with the applicable product reference safety information.

Time frame:
Baseline (Day 1) up to 24 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Unexpected Adverse Events (AEs)
Percentage of participantsCanagliflozin + Metformin Hydrochloride FDC
Percentage of Participants With Unexpected Adverse Events (AEs)0
SecondaryPercent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24

Percent change from baseline in HbA1c at Weeks 12 and 24 was reported.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · Percent change
Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24
Percent changeCanagliflozin + Metformin Hydrochloride FDC
Percent change at Week 12-0.918 ± 1.1348
Percent change at Week 24-0.926 ± 1.3054
PrimaryPercentage of Participants With Adverse Drug Reactions (ADRs)

ADRs were defined as the treatment related TEAEs. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were defined as events that started on or after the study medication start date and time.

Time frame:
Baseline (Day 1) up to 24 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Drug Reactions (ADRs)
Percentage of participantsCanagliflozin + Metformin Hydrochloride FDC
Percentage of Participants With Adverse Drug Reactions (ADRs)10.6

Adverse events

Collected over Baseline (Day 1) up to end of study (28 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Canagliflozin + Metformin Hydrochloride FDC0/274 (0%)3/274 (1.1%)114/274 (41.6%)
Most frequent serious events
Most frequent serious events
EventCanagliflozin + Metformin Hydrochloride FDC
Urinary Tract InfectionInfections and infestations2/274
COVID-19Infections and infestations1/274
Diabetic KetoacidosisMetabolism and nutrition disorders1/274
ProstatomegalyReproductive system and breast disorders1/274
Most frequent other events
Showing 10 of 87
Most frequent other events
EventCanagliflozin + Metformin Hydrochloride FDC
PyrexiaGeneral disorders13/274
DyslipidaemiaMetabolism and nutrition disorders13/274
Genital InfectionInfections and infestations9/274
HypoglycaemiaMetabolism and nutrition disorders9/274
Urinary Tract InfectionInfections and infestations7/274
AstheniaGeneral disorders5/274
COVID-19Infections and infestations5/274
ArthralgiaMusculoskeletal and connective tissue disorders5/274
Pain in ExtremityMusculoskeletal and connective tissue disorders5/274
ProteinuriaRenal and urinary disorders5/274

Baseline characteristics

Safety analysis set included all participants who had taken at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Canagliflozin + Metformin Hydrochloride FDC
Mean52.1 ± 8.34
Sex: Female, Male
Sex: Female, Male(Participants)Canagliflozin + Metformin Hydrochloride FDC
Female106
Male168
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Canagliflozin + Metformin Hydrochloride FDC
Indian274
Region of Enrollment
Region of Enrollment(Participants)Canagliflozin + Metformin Hydrochloride FDC
India274
08

Study locations

10 sites
  • Lifecare Hospital and Research Centre
    Bengaluru, 560092, India
  • Post Graduate Institute of Medical Education And Research PGIMER
    Chandigarh, 160012, India
  • Kovai Diabetes Specialty Centre & Hospital
    Coimbatore, 641 009, India
  • Excelcare Hospitals (A unit of Asclepius Hospitals and Health Care Pvt. Ltd.)
    Guwahati, 781033, India
  • Thumbay Hospital New life / Endocrinology
    Hyderabad, 500024, India
  • Fortis Hospital
    Mohali, 160062, India
  • Jehangir Clinical Development Center Pvt Ltd
    Pune, 411001, India
  • Chellaram Diabetes Institute
    Pune, 411021, India
  • Nirmal Hospital Pvt. Ltd.
    Surat, 395002, India
  • Jothydev's Diabetes Research Centre
    Trivandrum, 695032, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jul 2022, 20 months.

Results were first posted in Aug 2023, 1 year after primary completion.

Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 20 months is above that.

Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2020
First posted
Feb 28, 2020
StartActual
Nov 25, 2020
Primary completionActual
Jul 26, 2022
CompletionActual
Jul 26, 2022
Results first posted
Aug 18, 2023
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04288778
Responsible party
Sponsor
First posted
Feb 28, 2020
Start date
Nov 25, 2020
Primary completion
Jul 26, 2022
Completion
Jul 26, 2022
Results posted
Aug 18, 2023
Last update
Mar 30, 2025

Study contacts

Johnson & Johnson Private Limited Clinical Trial
study director · Johnson & Johnson Private Limited

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Canagliflozin · Metformin

Start the discussion